A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma
Status:
Completed
Trial end date:
2016-10-13
Target enrollment:
Participant gender:
Summary
This Phase II, randomized, double-blind, placebo-controlled, multicenter study will evaluate
the effects of lebrikizumab on airway eosinophilic inflammation in participants with
uncontrolled asthma who are using inhaled corticosteroid (ICS) treatment and a second
controller medication. Enrolled participants will undergo a 3-week screening period during
which assessments, including a bronchoscopy procedure, will be made. Participants will
subsequently be randomized to receive lebrikizumab or placebo by subcutaneous (SC) injection
on Day 1, Day 8, Week 4, and Week 8. Participants will continue their standard of care
therapy throughout the study. End of treatment assessments will be taken at Week 12. Total
study period, including screening and follow-up, is expected to last 23 weeks.